Pretargeted radioimmunotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  Meredith, Ruby F ^a   Buchsbaum, Donald J ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Lymphoma; Pretargeted radioimmunotherapy; Radioimmunotherapy

Indexed keywords

AMINES; ANTIBODIES; DOSIMETRY; IMMUNOLOGY; MEDICAL APPLICATIONS; TUMORS;

LYMPHOMA; PRETARGETED RADIOIMMUNOTHERAPY; RADIOIMMUNOTHERAPY;

RADIOTHERAPY;

BIOTIN; CD20 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; N ACETYLGALACTOSAMINE; PEPTIDE; REAGENT; STREPTAVIDIN; TUMOR ANTIGEN; YTTRIUM 90;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER MODEL; CANCER TISSUE; CIRCULATION; CLINICAL TRIAL; CONJUGATE; CROSS LINKING; DRUG BINDING; DRUG TARGETING; HUMAN; ISOTOPE LABELING; LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TREATMENT RESPONSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; BIOTIN; CLINICAL TRIALS, PHASE I; HUMANS; MICE; MICE, NUDE; MODELS, ANIMAL; NEOPLASMS; RADIOIMMUNOTHERAPY; STREPTAVIDIN; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 33748472553     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.04.058     Document Type: Article

References (10)

1. Boerman O.C., van Schaijk F.G., Oyen W.J.G., et al. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 44 (2003) 400-411
2. Goodwin D.A., and Meares C.F. Pretargeted peptide imaging and therapy. Cancer Biother Radiopharm 14 (1999) 145-152
3. Sharkey R.M., Karacay H., Cardillo T.M., et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11 (2005) 7109s-7121s
4. Sung C., and van Osdol W.W. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 36 (1995) 867-876
5. Chen J.Q., Strand S.E., Tennvall J., et al. Extracorporeal immunoadsorption compared to avidin chase: Enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med 38 (1997) 1934-1939
6. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97 (2000) 1802-1807
7. Weiden P.L. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma. Leuk Lymphoma 43 (2002) 1971-1973
8. Forero A., Weiden P.L., Vose J.M., et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104 (2004) 227-236
9. Shen S., Forero A., LoBuglio A.F., et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46 (2005) 642-651
10. Wiseman G.A., White C.A., Stabin M., et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27 (2000) 766-777